The Ellipta inhaler
About us We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Read morePress releases
- GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER
- Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD
- Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD
Tweets from GSK
-
GSK @GSK
Let’s get #readytobeatmalaria on #WorldMalariaDay and every day cards.twitter.com/cards/ob0hpq/5…
about 3 hours ago
-
GSK @GSK
Guidance for CER growth in Adjusted EPS for 2018 maintained. $GSK Full details: cards.twitter.com/cards/ob0hpq/5…
about 5 hours ago
-
GSK @GSK
19p dividend declared for quarter. Continue to expect 80p for FY 2018. $GSK Full details: cards.twitter.com/cards/ob0hpq/5…
about 5 hours ago
